PHARMACEUTICAL 2018

Monopar Therapeutics
Rank 203 of 332

Monopar Therapeutics



RealRate

PHARMACEUTICAL 2018

Monopar Therapeutics
Rank 203 of 332

Monopar Therapeutics

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 83% points.The greatest weakness of Monopar Therapeutics is the variable Other Expenses, reducing the Economic Capital Ratio by 182% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 33% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	9,131
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	312
Liabilities, Non-Current	0
Other Assets	800
Other Compr. Net Income	0
Other Expenses	14,502
Other Liabilities	0
Other Net Income	48
Other Revenues	0
Property and Equipment	0
Research and Development	935
Selling, General and Administrative Expense	1,166

Output Variable	Value in 1000 USD
Assets	9,931
Liabilities	312
Expenses	16,603
Revenues	0
Stockholders Equity	9,619
Net Income	-16,555
Comprehensive Net Income	-16,555
BaseVar	13,447
ECR before LimitedLiability	86%
Economic Capital Ratio	219%